The Slow Newscast
The Sacklers: Getting away with it
May 14, 2024
The Sackler family, billionaires from OxyContin, face legal battles amidst the opioid crisis. Podcast delves into legal troubles, lifestyle, personal stories of addiction, and the controversies surrounding Sackler deal and Mundi Pharma's opioid sales. It explores the urgent need for recovery and treatment initiatives.
44:27
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The Sackler family profited from OxyContin sales, facing minimal accountability for epidemic they fueled.
- Despite legal scrutiny and tax payments, the Sacklers remain wealthy, raising questions on their accountability.
Deep dives
The Impact of OxyContin and the Role of the Sackler Family
OxyContin, a potent and addictive opioid painkiller, unleashed an epidemic in the US, causing tens of thousands of deaths annually. The Sackler family, linked through Purdue Pharma, profited from OxyContin sales but faced minimal accountability for the crisis they fueled. As the US Supreme Court decides on a $6 billion settlement involving the Sacklers, victims may receive compensation, but the family would secure immunity from civil litigation.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
